163
Participants
Start Date
December 5, 2017
Primary Completion Date
November 9, 2018
Study Completion Date
November 27, 2018
Aflibercept (Eylea, BAY86-5321)
"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
Many Locations, Multiple Locations
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Bayer
INDUSTRY